Disease Monitoring In Multiple Myeloma
Jens Hillengass 1 , Tom Martin 2 , Noemi Puig 3 , Bruno Paiva 4 , Saad Usmani 5 , Shaji Kumar 6 , Jesus San-Miguel 7
The outcome for multiple myeloma (MM) patients has significantly improved in the last two decades, mainly due to the use of novel drugs with a singular mechanism of action, including immunotherapy.
This has sparked a new debate about the possibility of curing a substantial proportion of MM patients which implicitly entails the need for most sensitive tools for evaluating treatment efficacy and disease monitoring (minimal residual disease –MRD) both at the Bone marrow (BM) level (next generation flow cytometry (NGF) and sequencing) and outside of the BM (magnetic resonance imaging [MRI]/positron emission tomography [PET] computed tomography [CT], mass spectrometry).
CITATION Clin Lymphoma Myeloma Leuk. 2023 Jan 14;S2152-2650(23)00017-4. doi: 10.1016/j.clml.2023.01.005